|
MNOV, DSCO, CEDC, BTDG, CTCC, CAMS
Our Stocks to Watch tomorrow include MediciNova Inc. (NASDAQ: MNOV), Discovery Laboratories Inc. (NASDAQ: DSCO), Central European Distribution Corp. (NASDAQ: CEDC), B2 Digital Inc. (OTC: BTDG), City Capital Corp. (OTC: CTCC) and Cambrian Systems Inc. (OTC: CAMS).
MEDICINOVA INCORPORATED (NASDAQ: MNOV)
"Up 30.16% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/MNOV.php
MediciNova, Inc. is a publicly traded biopharmaceutical company founded upon acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet need with a commercial focus on the U.S. market. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential, and patent coverage of commercially adequate scope. MediciNova's pipeline includes six clinical-stage compounds for the treatment of acute exacerbations of asthma, chronic obstructive pulmonary disease exacerbations, multiple sclerosis and other neurologic conditions, asthma, interstitial cystitis, solid tumor cancers, Generalized Anxiety Disorder, preterm labor and urinary incontinence and two preclinical-stage compounds for the treatment of thrombotic disorders. MediciNova's current strategy is to focus on its two prioritized product candidates, MN-221, for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease exacerbations, and ibudilast (MN-166/AV411). Each drug candidate is involved in clinical trials under U.S. and Investigator INDs. MediciNova is engaged in strategic partnering discussions to support further development of the MN-221 and ibudilast programs. Additionally, MediciNova will seek to monetize opportunistically its other pipeline candidates.
MNOV News:
February 1 - MediciNova Receives a Notice of Patent Allowance for a Method of Treating Progressive Multiple Sclerosis
Claims Cover the Use of Ibudilast for Primary or Secondary Progressive Multiple Sclerosis
MediciNova Inc. (NASDAQ: MNOV), a biopharmaceutical company traded on the NASDAQ Global Market and the Jasdaq Market of the Osaka Securities Exchange (4875), announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application, which covers the use of ibudilast for the treatment of progressive forms of multiple sclerosis. Ibudilast (MN-166), is the company's lead drug development candidate for certain neurological conditions, including progressive multiple sclerosis, neuropathic pain, and drug addiction.
A patent maturing from this allowed patent application is expected to expire no earlier than early 2029 and covers a method of treating primary progressive multiple sclerosis (PPMS) or secondary progressive MS (SPMS) by administering ibudilast either alone or in combination with other drugs. The patent application is based upon clinical investigations conducted by MediciNova researchers which showed an apparent disease-modifying benefit in which brain volume loss, or brain atrophy, commonly associated with disease progression, was reduced by oral administration of ibudilast to a group of multiple sclerosis patients including some subjects with progressive multiple sclerosis, in a dose-related fashion over at least a 10-month treatment period.
Multiple sclerosis (MS) is recognized as a chronic disease in which disability progresses over time. Patients suffering from progressive forms of MS tend to have a poor prognosis and have greater levels of disability. Robert J. Fox, M.D., M.S., FAAN, Medical Director of Mellen Center for MS, Cleveland Clinic, noted that, "Despite recent improvements in pharmacotherapy for relapsing remitting multiple sclerosis, treatment options in progressive multiple sclerosis are extremely limited in the absence of relapses. There is great need for safe, effective, and conveniently-administered therapies for progressive MS."
Obtaining long-term protection of market exclusivity for the use of ibudilast in certain neurological conditions has been a key component of MediciNova's development strategy for the MN-166 program. Yuichi Iwaki, M.D., Ph.D., President and Chief Executive Officer of MediciNova, noted that, "We are very pleased to receive notice of this patent allowance for ibudilast in progressive MS. Moreover, we anticipate that this allowance will facilitate further development and business options around this program."
ABOUT IBUDILAST
Ibudilast has been used in asthma and post-stroke disorders in Japan for around 20 years. MediciNova has demonstrated the potential utility of ibudilast in the treatment of neurological disorders at higher doses with encouraging outcomes in company-sponsored clinical trials in multiple sclerosis (MS) and neuropathic pain. MediciNova's collaborative trial planning with drug addiction investigators at organizations like Columbia/NYSPI and UCLA has led to National Institute on Drug Abuse (NIDA)-to support clinical investigations of the use of ibudilast to treat both opioid and methamphetamine addiction. A Phase 2 investigator-sponsored trial of ibudilast in the treatment of chronic medication overuse headache (MOH) pain is also ongoing in Australia. MediciNova's priorities include pursuing Phase 2 proof-of-concept trials of ibudilast for the treatment of progressive MS and/or neuropathic pain through non-dilutive funding.
DISCOVERY LABS INCORPORATED (NASDAQ: DSCO)
"Up 14.35% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/DSCO.php
Discovery Laboratories, Inc. is a biotechnology company developing Surfactant Therapies for respiratory diseases. Surfactants are produced naturally in the lungs and are essential for breathing. Discovery Labs' novel proprietary KL4 Surfactant Technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, aerosol or lyophilized formulations. In addition, Discovery Labs' proprietary Capillary Aerosolization Technology produces a dense aerosol, with a defined particle size that is capable of potentially delivering aerosolized KL4 surfactant to the deep lung without the complications currently associated with liquid surfactant administration. Discovery Labs is focused initially on developing its KL4 surfactant pipeline to build a pediatric franchise that will potentially address several respiratory conditions affecting neonates and young children, beginning with Respiratory Distress Syndrome (RDS).
DSCO News:
February 2 - Discovery Labs Cleared to Market AFECTAIR in U.S.
New, Proprietary Technology Simplifies Delivery of Aerosolized Medications to Patients Requiring Ventilatory Support
Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced AFECTAIR® is now registered with the Food and Drug Administration (FDA) and is cleared to be marketed in the United States. AFECTAIR is a proprietary patient interface technology that simplifies delivery of aerosolized medications to patients requiring ventilator support.
"We are pleased to have AFECTAIR registered with the FDA and we are eager to move this proprietary technology to commercialization in the latter part of 2012," said W. Thomas Amick, Chairman of the Board and Chief Executive Officer of Discovery Labs. "Our ability to bring AFECTAIR to market is a testament to our commitment to advancing a new standard in respiratory critical care."
AFECTAIR originates from the AEROSURF® development program and is a proprietary disposable ventilator circuit/patient interface connector that simplifies the delivery of aerosolized medications to critical-care patients requiring ventilatory support from either intermittent mechanical ventilation or continuous positive airway pressure. To date, in vitro studies suggest that the AFECTAIR technology may be an effective new solution for delivering aerosolized medicine to patients receiving ventilator support while providing healthcare professionals with a simplified alternative to current practices. According to national health statistics and market assessment data, it is estimated that each year more than 1.3 million patients in the United States and European Union receive aerosolized medications while requiring ventilator support. It is estimated that AFECTAIR represents a potential revenue opportunity of approximately $50-75 million for Discovery Labs.
"In preparation for this milestone, we identified a number of operational and commercial options intended to support the commercial introduction of AFECTAIR," said Thomas F. Miller, Senior Vice President and Chief Operating Officer of Discovery Labs, "We are now focused on implementing a commercial plan that includes the establishment of key strategic manufacturing and distribution relationships."
Discovery Labs is also pursuing a European Conformity (CE) marking for commercialization of the initial AFECTAIR products in the European Union (EU) and believes that it may be in a position to initiate the commercial introduction of the initial AFECTAIR products in EU in late 2012.
ABOUT AFECTAIR
AFECTAIR is a series of proprietary ventilator circuit/patient interface connectors and related componentry. AFECTAIR simplifies the delivery of inhaled therapies to critical care patients requiring ventilatory support. According to national health statistics and market assessment data, it is estimated that each year more than 1.3 million patients in the United States and European Union receive aerosolized medications while requiring ventilator support. Discovery Labs is implementing a business plan that potentially will allow for the commercial introduction of AFECTAIR in the United States and the European Union in 2012.
ABOUT AEROSURF
AEROSURF (lucinactant for inhalation), Discovery Labs' initial aerosolized KL4 surfactant product, is under development for the prevention of RDS in premature infants. Through effective delivery of aerosolized KL4 surfactant using Discovery Labs' proprietary capillary aerosol generator technology and related ventilator circuit / patient interface connectors, AEROSURF may significantly expand the surfactant-eligible treatment population by providing neonatologists with a means of administering surfactant without the risks currently associated with surfactant administration, which requires invasive endotracheal intubation and mechanical ventilation.
CENTRAL EUROPEAN DISTRIBUTION (NASDAQ: CEDC)
"Up 18.39% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/CEDC.php
Central European Distribution Corporation, together with its subsidiaries, produces, imports, and distributes alcoholic beverages in Poland, Hungary, and the Russian Federation. It produces and sells vodka under the Absolwent, Zubrowka, Bols, Palace, Soplica, Green Mark, Parliament, Zhuravli, and Royal brands. The company distributes approximately 700 brands of alcoholic beverages; and imports spirits, wines, and beers of various brands, including Jim Beam Bourbon, Campari, Jägermeister, Remy Martin Cognac, Guinness, Corona, Budvar, E&J Gallo wines, Carlo Rossi wines, Sutter Home wines, Metaxa Brandy, Sierra Tequila, Teacher’s Whisky, Cinzano, Old Smuggler, Grant’s Whisky, and Concha y Toro wines. It also exports its products principally to Ukraine, Commonwealth of Independent States, the United States, Japan, the United Kingdom, and France. The company was founded in 1990 and is based in Mt. Laurel, New Jersey.
CEDC News:
January 30 - CEDC Signs an Agreement With William Grant and Sons for the Exclusive Distribution of Green Mark, Zubrowka and Kauffman Vodka in the UK PR Newswire
Central European Distribution Corporation (NASDAQ: CEDC), one of the leading vodka producers in the world, would like to announce that First Drinks Brands, part of William Grant & Sons, will have the exclusive importation rights to Green Mark, Zubrowka and Kauffman Vodka in the United Kingdom. The agreement strengthens CEDC and William Grant & Sons' international alliance, within which CEDC imports and distributes brands from William Grant & Sons' portfolio in Poland and Hungary.
Green Mark is the no. 1 vodka brand in the Russian market and one of the top vodka brands in the world, with annual sales of approximately 10 million 9-liter cases worldwide. It is a genuine Russian vodka with international recognition, noting dynamic growth of export.
Zubrowka Bison Grass Vodka is CEDC's flagship export brand in Poland. It is a vodka with over 600-years of tradition and a unique flavor derived from "bison grass," an aromatic plant from Poland's cleanest region of Podlasie. Zubrowka is sold throughout the world in over 50 countries and is a leading imported vodka brand in France, Japan and the UK. The brand sold approx.1 million 9l cases globally in 2010.
Kauffman Vodka is a super-premium vodka brand and the first vintage vodka in the world.
"We are pleased to enter into partnership with the strongest distributor in the UK, with great experience in building premium brands in the market. We believe First Drinks Brands will contribute to further expansion of Green Mark which as an authentic, high quality vodka from Russia has great sales potential in the UK, where vodka is the largest spirits category." - said William Carey, President and CEO of CEDC and continued – "We have been very successful in expanding Green Mark's export in 2011, winning 7% market share in Ukraine and we will continue to build this brand's international presence. We also look forward to strengthening the position of Zubrowka which is our key export brand and has already won recognition in the UK market."
Chris Mason, Managing Director of First Drinks, comments: "We are delighted to be working with CEDC, one of the world's leading vodka producers and look forward to a long term partnership to achieve our ambitious, mutual goals. The new vodkas are an excellent fit within our existing portfolio, complementing our current brands. We have a strong track record of building premium brands and have big ambitions for 2012 to be in the position to offer our customers the most desired portfolio of authentic vodka brands of any UK distributor.
"As industry leaders in the UK premium spirits market, our strategy is to build on our reputation as premium brand builders and have a full range of authentic vodkas relevant to both the on and off-trade," concludes Mason.
CEDC represents William Grant & Sons' portfolio in Poland and Hungary, including Grant's Glenfiddich and Balvenie Scotch whisky, Hendrick's Gin and Tullamore Dew Irish whiskey. CEDC has been present in the UK market with its Zubrowka , Soplica and Graduate brands. First Drinks Brands will be distributing Green Mark and Kauffman Vodka starting from 1st quarter of 2012 and Zubrowka starting from 2nd half of 2012.
B2DIGITAL INCORPORATED (OTC: BTDG)
"Up 100.00% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/BTDG.php
B2 Digital is dedicated to seeking acquisitions, mergers and joint ventures with a scope of business opportunities including the resource sector. With a merger of this type B2 Digital will become a part of one great organization, SSM Media Ventures, Inc. and RHN.
BTDG News:
August 30 - SSM Media Ventures Signs Acquisition Agreement With B2 Digital, Inc.
B2 Digital, Inc. (OTC: BTDG) has signed an acquisition agreement with SSM Media Ventures, Inc. for the purchase of 51% of the Common Shares of B2 Digital, Inc.
On August 25, 2011, B2 Digital, Inc. (the Company) and SSM Media Ventures, Inc. (the holding Company of "Real Hip Hop Network"), signed a Merger Agreement for the purchase of 51% of the Common Stock and all unissued stock of B2 Digital. The cash offer from SSM Media Ventures, Inc. is in the amount of $2,050,011.82.
CEO & President of SSM Media Ventures, Inc., Atonn F. Muhammad, stated, "In moving forward with our subsidiary RHN launching into the Hip-Hop Markets soon, delivery of the content is critical to our overall success. Having done a share exchange with B2 Digital earlier this year has shown what B2 Digital has to offer in making many of our challenges easier to overcome. We feel we could not have found a better Company to work with by utilizing B2 Digital technology and its experience. As we reach our launch dates into the Hip-Hop Markets we now know that it will be with high quality digital performance and proven security."
The market for Hip-Hop is truly expansive and global; with an estimated 100 million fans worldwide, including 50 million in the U.S. alone, as reported by Business Week. Hip-Hop is here to stay and is the second largest selling music category, trailing only Country (for which, by comparison, there are already three dedicated cable networks). There are at least two Hip-Hop radio stations ranked among the top 10 (based on listener data) in nine of the ten largest U.S. Markets.
B2 Digital CEO & President, Paul D.H. LaBarre, stated, "All of us at B2 Digital are very excited to become involved with a cutting edge company like SSM Media Ventures and RHN. We have always placed the highest priority on creating the maximum value for our shareholders. With this in mind came our decision to focus our efforts on the Media world. Over the past several months it is proven that we are moving in the right direction. In accepting this offer from SSM Media Ventures, Inc., we at B2 Digital see a great opportunity with RHN as Mr. Muhammad and his staff advance into the Markets."
SSM Media Ventures plans to structure a series of capital infusions into B2 Digital and raise capital for future acquisitions and existing operations to include other SSM Media Ventures related properties: (Legacy Fund & (RHN) The Real Hip-Hop Network).
ABOUT SSM MEDIA VENTURES
SSM Media Ventures Inc.is a premiere private equity group with a growing portfolio of companies. SSM's core concentration is in telecommunications, mobile technology, cable, internet and media. The firm currently owns controlling interest of The Real Hip-Hop Network and Legacy Fund.
CITY CAPITAL CORPORATION (OTC: CTCC)
"Up 133.33% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/CTCC.php
City Capital Corporation, founded in 1984, is a leader in the production and distribution of emerging new gaming technology. Its holdings include corporate owned retail stores and partnerships across the nation. City Capital also maintains its long track-record of both building value for investors and shareholders, while keeping with its socially responsible focus. A significant share of profits are donated to charity and other worthwhile causes.
CTCC News:
January 12 - New Acquisition Offers Solar Power and LED Lighting Nationwide
Having a firm belief that Green Energy is a sound investment as a necessity for the world's future energy requirements, City Capital Corporation (OTC: CTCC) has acquired Strategic Energy and Power (STEP), a Nevada-based startup that manufactures, installs, sells and distributes solar installations and LED lighting. It also has proprietary technology that promises to be the future of the industry.
"The company is particularly enthused about its adaptation for terrestrial use of solar generators previously used only in space applications," said company CEO Donald MacIntyre. "We're also in the process of patenting a system that captures off-angle solar energy without the use of a tracking device that will allow much more efficient and inexpensive generation of solar power. Green Energy is still in its infancy, and we're excited about becoming a leader in this growth industry."
With distribution and installation agreements already in place, the company offers solar and LED installation for both residential and commercial applications around the country. Talks are upcoming with several Native American entities for systems to meet their needs, and plans are underway to bid competitively for governmental contracts.
CAMBRIAN SYSTEMS INCORPORATED (OTC: CAMS)
"Up 50.00% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/CAMS.php
Cambrian is an independent oil and gas company with a primary focus on acquiring, developing and participating in the U.S. crude oil and natural gas properties.
CAMS News:
January 18 - Cambrian Announces Corporate Update
Cambrian Systems (OTC: CAMS) announces that it is making very good progress in Kentucky.
As we stand today, Cambrian Systems is predominantly an independent oil and gas company with a primary focus on acquiring, developing and participating in crude oil and natural gas properties. The past four months have been highly productive for Cambrian. We now have acquired just over 500 acres of oil leases. Significant revenue opportunities exist through the development of the existing wells and the reactivation of the shut-in wells.
Currently, our operator has been carrying out appraisal and development studies. The principal objective of the 2012 work program is to assess and plan for the commercialization of our prospective resources and to explore ways to exploit these Wells with an early production scheme to generate early cash flows. The Company constantly reviews investment opportunities that will increase our exploration and production asset portfolio and will target value accretive acquisitions which may require additional funding in the future.
We are also proud to announce that within the next two weeks we expect to fully equip and put one well into production on our 250 acre King lease in Green County, Kentucky.
Over the ensuing weeks we'll be closely monitoring and working to maximize production from this well. Assuming we achieve commercially viable production amounts, we'll use the same production-enhancing techniques employed on this well as a blueprint as we move forward with equipping and getting production from other wells on our block of leases in Green County.
|
